RU99118587A - A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, METHOD OF ITS PRODUCTION AND ITS APPLICATION - Google Patents

A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, METHOD OF ITS PRODUCTION AND ITS APPLICATION

Info

Publication number
RU99118587A
RU99118587A RU99118587/14A RU99118587A RU99118587A RU 99118587 A RU99118587 A RU 99118587A RU 99118587/14 A RU99118587/14 A RU 99118587/14A RU 99118587 A RU99118587 A RU 99118587A RU 99118587 A RU99118587 A RU 99118587A
Authority
RU
Russia
Prior art keywords
composition according
bulk density
inhalation
pharmaceutically active
production
Prior art date
Application number
RU99118587/14A
Other languages
Russian (ru)
Other versions
RU2194497C2 (en
Inventor
Ян Трофаст
Original Assignee
Астра Актиеболаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9700135A external-priority patent/SE9700135D0/en
Application filed by Астра Актиеболаг filed Critical Астра Актиеболаг
Publication of RU99118587A publication Critical patent/RU99118587A/en
Application granted granted Critical
Publication of RU2194497C2 publication Critical patent/RU2194497C2/en

Links

Claims (9)

1. Сухая порошкообразная композиция, содержащая одно или более чем одно сильнодействующее фармацевтически активное вещество и вещество-носитель, которые находятся в тонко измельченной форме, причем препарат имеет насыпную объемную плотность 0,28 - 0,38 г/мл.1. A dry powder composition containing one or more potent pharmaceutically active substances and carrier substances that are in finely divided form, the preparation having a bulk density of 0.28-0.38 g / ml. 2. Композиция по п. 1, где одно или более чем одно сильнодействующее фармацевтически активное вещество представляет собой будесонид и формотерол. 2. The composition according to p. 1, where one or more than one potent pharmaceutically active substance is budesonide and formoterol. 3. Композиция по п. 1 или 2, где объемная плотность составляет 0,30 - 0,36 г/мл. 3. The composition according to p. 1 or 2, where the bulk density is 0.30 - 0.36 g / ml 4. Композиция по п. 1, 2 или 3, где активное вещество и вещество-носитель по существу однородно распределены. 4. The composition according to p. 1, 2 or 3, where the active substance and the carrier substance are essentially uniformly distributed. 5. Композиция по любому из пп. 1-4 для применения при лечении респираторного расстройства. 5. The composition according to any one of paragraphs. 1-4 for use in the treatment of respiratory disorder. 6. Способ получения композиции по п. 1, при котором: (а) микронизируют одно или более чем одно сильнодействующее фармацевтически активное вещество и вещество-носитель; (б) возможно приводят этот продукт в соответствие с нормами; и (в) сферонизируют до тех пор, пока не будет получена желаемая объемная плотность. 6. A method for producing a composition according to claim 1, wherein: (a) one or more potent pharmaceutically active substances and a carrier substance are micronized; (b) it is possible to bring this product into compliance with the standards; and (c) spheronized until the desired bulk density is obtained. 7. Способ по п. 6, который включает в себя стадию повторной микронизации низкой энергии после стадии (б). 7. The method according to p. 6, which includes the stage of re-micronization of low energy after stage (b). 8. Применение композиции по любому из пп. 1-4 в производстве лекарства для использования в терапии. 8. The use of the composition according to any one of paragraphs. 1-4 in the manufacture of a medicament for use in therapy. 9. Способ лечения пациента, страдающего респираторным расстройством, при котором пациенту вводят терапевтически эффективное количество композиции по любому из пп. 1-4. 9. A method of treating a patient suffering from a respiratory disorder in which a therapeutically effective amount of a composition according to any one of claims is administered to a patient. 1-4.
RU99118587/14A 1997-01-20 1998-01-13 Novel inhalation preparation with filled volume density from 0,28 to 0,38 g/ml, method of its preparing and its using RU2194497C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700135-8 1997-01-20
SE9700135A SE9700135D0 (en) 1997-01-20 1997-01-20 New formulation

Publications (2)

Publication Number Publication Date
RU99118587A true RU99118587A (en) 2001-06-27
RU2194497C2 RU2194497C2 (en) 2002-12-20

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99118587/14A RU2194497C2 (en) 1997-01-20 1998-01-13 Novel inhalation preparation with filled volume density from 0,28 to 0,38 g/ml, method of its preparing and its using

Country Status (35)

Country Link
US (2) US6030604A (en)
EP (1) EP1007017B2 (en)
JP (1) JP2010059181A (en)
KR (1) KR100528416B1 (en)
CN (1) CN1271993C (en)
AR (1) AR011080A1 (en)
AT (1) ATE288260T1 (en)
AU (1) AU731192B2 (en)
BR (1) BR9811249A (en)
CA (1) CA2277913C (en)
CZ (1) CZ296301B6 (en)
DE (1) DE69828886T3 (en)
DK (1) DK1007017T4 (en)
EE (1) EE03951B1 (en)
ES (1) ES2235311T5 (en)
HK (1) HK1025515A1 (en)
HU (1) HU228622B1 (en)
ID (1) ID21865A (en)
IL (1) IL130838A (en)
IS (1) IS2788B (en)
MY (1) MY132999A (en)
NO (1) NO327426B1 (en)
NZ (1) NZ336594A (en)
PL (1) PL192115B1 (en)
PT (1) PT1007017E (en)
RU (1) RU2194497C2 (en)
SA (1) SA98180818B1 (en)
SE (1) SE9700135D0 (en)
SI (1) SI1007017T2 (en)
SK (1) SK283950B6 (en)
TR (1) TR199901690T2 (en)
TW (1) TW557217B (en)
UA (1) UA57764C2 (en)
WO (1) WO1998031352A1 (en)
ZA (1) ZA9878B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (en) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
WO2000035417A1 (en) * 1998-12-11 2000-06-22 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
AR022695A1 (en) * 1999-01-28 2002-09-04 Schering Corp SOLID PARTICULATE CARRIER AND METHOD TO PROVIDE PARTICULATE CONTROL FOR THE DISTRIBUTION OF SIZE OF PARTICLES AND CONVERTIBLE AMORPH CONTENT DURING PREPARATION
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
AU779869B2 (en) * 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
CA2273585A1 (en) 1999-05-28 2000-11-28 Canpolar East Inc. Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure
DE19962926A1 (en) * 1999-12-24 2001-06-28 Bayer Ag Comminution of a substance, especially a cardiovascular drug, comprises mixing the substance with lactose and comminuting the mixture in a jet mill
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (en) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination for asthma therapy
FI20002216A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
ATE369121T1 (en) * 2001-02-06 2007-08-15 Innovata Biomed Ltd BIMODAL DRY POWDER COMPOSITION FOR INHALATION
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AR036358A1 (en) * 2001-08-28 2004-09-01 Schering Corp A DOSE INHALER MEASURES CONTAINING A SUSPENSION FORMULATION IN AEROSOL FOR INHALATION, A PROCESS FOR THE PRODUCTION OF THE FORMULATION, THE PRODUCT AND THE USE OF A FORMULATION FOR THE MANUFACTURE OF AN ASTHMA MEDICINAL PRODUCT
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
MXPA04011018A (en) * 2002-05-07 2005-01-25 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders.
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
DK1572217T3 (en) * 2002-12-12 2008-12-15 Nycomed Gmbh Combination drug of R, R-formoterol and ciclesonide
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
AU2004241746A1 (en) * 2003-05-22 2004-12-02 Nycomed Gmbh Salmeterol and ciclesonide combination
SE526509C2 (en) * 2003-06-19 2005-09-27 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE526850C2 (en) * 2003-06-19 2005-11-08 Microdrug Ag Pharmaceutical combined dry powder dose separated on common dose bed
SE527200C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527189C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
ATE498394T1 (en) 2003-09-02 2011-03-15 Norton Healthcare Ltd METHOD FOR PRODUCING A MEDICATION
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DE602005002930T2 (en) * 2004-01-22 2008-07-24 Pfizer Inc. SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
JO3102B1 (en) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
AR048339A1 (en) * 2004-03-24 2006-04-19 Chiesi Farma Spa 8- HYDROXI-5 MONOCLORHYDRATE - ((1R)) -1- HYDROXI-2- (((1R) -2 (4-METOXIFENIL) -1- METHYLETYL) AMINO) ETI L) -2 (1H) - QUINOLINONE EN ACRISTALINE FORM AND THE PROCESS FOR PREPARATION
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
EP1744800B1 (en) 2004-04-21 2016-06-22 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
WO2006064283A1 (en) * 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions
CN104177448A (en) * 2005-02-10 2014-12-03 葛兰素集团有限公司 Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom
ES2384641T3 (en) 2005-07-14 2012-07-10 Lithera, Inc. Lipolytic formulation that enhances the release maintained for the localized treatment of adipose tissue
CN103462943A (en) * 2005-07-15 2013-12-25 Map药物公司 Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007009164A1 (en) * 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
PL2077830T3 (en) * 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
WO2008100727A2 (en) 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (en) 2007-10-18 2009-04-23 Pharmatech Gmbh Apparatus and method for the continuous production of spherical powder agglomerates
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CA2763939A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20120113267A (en) * 2010-01-15 2012-10-12 리쎄라 인코오포레이티드 Lyophilized cake formulations
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
US10179139B2 (en) 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
US9402854B2 (en) 2012-04-11 2016-08-02 Cipla Limited Pharmaceutical composition
RU2510267C2 (en) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Inhalation preparation for treating bronchial asthma and chronic obstructive pulmonary disease and method for preparing it
KR102391332B1 (en) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 Methods and systems for conditioning of particulate crystalline materials
PL2821061T3 (en) 2013-07-01 2018-05-30 Arven Ilac Sanayi Ve Ticaret A.S. Novel inhalation formulations
CA3073195A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
MX2021014343A (en) * 2019-05-24 2022-01-06 Glenmark Pharmaceutical Ltd An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
SE438261B (en) * 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
EP0705614B1 (en) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
ES2044710T3 (en) † 1990-01-29 1994-01-01 Ciba Geigy Ag METHOD AND MEASURING DEVICE FOR A FINE GRANULOMETRY POWDER.
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (en) * 1991-02-04 1991-02-04 Astra Ab NOVEL STEROIDS
SE9100342D0 (en) * 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) * 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
PT656207E (en) * 1991-06-10 2001-11-30 Schering Corp AEROSOLS FORMULATIONS WITHOUT CHLOROFLUOROCARBONETS
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
ES2177544T3 (en) † 1992-06-12 2002-12-16 Teijin Ltd ULTRAFININE POWDER TO INHALATE AND METHOD FOR PREPARATION.
CA2147283C (en) * 1992-10-16 2007-01-16 Kouichi Nakamichi Method of manufacturing wax matrices
ES2125483T3 (en) * 1993-08-18 1999-03-01 Unilever Nv COMPOSITION FOR THE SHAVE.
IS1736B (en) * 1993-10-01 1999-12-30 Astra Ab Methods and devices that promote increased particle aggregation
HU222355B1 (en) † 1993-10-01 2003-06-28 Astra Aktiebolag Process and apparatus for treatment of finely divided powdered medicament
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (en) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation

Similar Documents

Publication Publication Date Title
RU99118587A (en) A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, METHOD OF ITS PRODUCTION AND ITS APPLICATION
RU99118589A (en) A NEW MEDICINE FOR INHALATION HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML CONTAINING BUDESONIDE
RU99118588A (en) A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, CONTAINING FORMOTEROL
ES2370729T3 (en) INFLATABLE PHARMACEUTICAL FORM INCLUDING GELLAN RUBBER.
KR100329249B1 (en) Nasal administration composition
RU2001123923A (en) Compositions comprising formoterol and tiotropium salt
RU2002116251A (en) Formoterol aerosol composition
RU2001126347A (en) Compositions including formoterol and mometason furoate for asthma
RU2000131218A (en) APPLICATION OF THE COMPOSITION CONTAINING FORMOTHEROL AND BUDESONIDE FOR THE PREVENTION OR TREATMENT OF ACUTE ASTHMA
HUP0102892A2 (en) Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use
RU2180563C2 (en) Preparation for inhalation with filled volume density from 0,28 to 0,38 g/ml containing budesonide
DE69527842D1 (en) LIQUID MEDICINAL PRODUCT CONTAINING ORAL ALENDRONATE
AR011080A1 (en) COMPOSITION IN DRY POWDER, PROCESS FOR ITS PREPARATION AND USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF THE MEDICINAL PRODUCT
AR017984A1 (en) PROCESS TO FORM A PHARMACEUTICAL COMPOSITION OF TOPIRAMATO AND PHARMACEUTICAL COMPOSITION OF TOPIRAMATO
RU2000106597A (en) NEW APPLICATION OF BUDESONIDE AND FORMOTHEROL
RU99118586A (en) A NEW MEDICINE FOR INHALATION HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, CONTAINING TERBUTALINE SULFATE, METHOD FOR PRODUCING AND ITS APPLICATION
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
RU2180562C2 (en) Preparation for inhalation with filled volume density from 0,28 to 0,38 g/ml and containing terbutaline sulfate, method of its preparing and its using
JPH0428685B2 (en)
US20240123168A1 (en) Product delivery devices and methods
RU2394579C2 (en) Application of ethinylestradiol and chlormadinone acetate combination for preparation of medication
RU2002124141A (en) APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS
HUP0002533A2 (en) New combination of antiasthma medicaments
RU2245157C2 (en) Biologically active additive for preventing and treating flu cases
CN108465036A (en) A kind of remedy,toothache and middle powder stick item